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Objective: This study determined the average estimated total costs after treatment for peripheral arterial occlusive disease
(PAOD) and evaluated the effect of postoperative complications and their consequences for the total costs.
Methods: Cost data on all admissions involving treatment for PAOD from January 2007 until July 2007 were collected.
A prospective analysis was made using the patient-related risk factor and comorbidity (Society for Vascular Surgery/
International Society of Cardiovascular Surgeons) classification, primary and secondary treatment, and prospectively
registered complications. At admission, patients without complications were placed in group A, and those with
complications were in group B. Prospectively registered complications were divided into patient management (I), surgical
technique (II), patient’s disease (III), and outside surgical department (IV). The consequences of these were divided into
minor complication, no long-term consequence (1A), additional medication or transfusion (1B), surgical reoperation
(2A), prolonged hospital stay (2B), irreversible physical damage (3), and death (4). The main outcome measures were
total costs of patients and costs per patient (PP), with or without the presence of complications, cost of complications and
costs per complication (PC), and the costs of their consequences calculated in euros (€).
Results: Ninety patients (mean age, 71.4 years; 59% men) were included. Group B patients had a significantly higher
American Society of Anesthesiologists (4) and Fontaine (3) classification and more secondary procedures. Total costs
were €1,716,852: group A, €512,811 (PP €12,820); and group B, €1,204,042 (PP €24,081). The costs of the 115
complications were €568,500 (PC €4943). Split by the cause of the complication, costs were I, €95,924 (PC €2998); II,
€163,137 (PC €8157); III, €289,578 (PC €5171); and IV, €19,861 (PC €2837). The increase of costs in group B was
mainly caused by additional medication or transfusion (1B) €348,293 (61.3%), a surgical reoperation (2A) €118,054
(20.8%), or prolonged hospital stay (2B) €60,451 (10.6%). Patients who died caused 23% of the total costs.
Conclusion: Complications cause an increase of the average estimated total costs in the treatment for peripheral arterial
occlusive disease and are responsible for 33% of these total costs. The most expensive complications were errors in surgical
technique and patient’s disease, resulting in surgical reoperation or additional medication, or both, or transfusion, the
two most expensive consequences. ( J Vasc Surg 2008;48:368-76.)In today’s society, cost containment is a goal that
extends into the health care sector. Rising health care costs
represent a critical issue that is important in decision mak-
ing. Insurance organizations are playing an increasingly
important role in the delivery of health care and will not
permit patients to be admitted to medical centers that
cannot deliver health care at lower costs than competing
hospitals. Medical specialists, in particular, are under signif-
icant pressure to decrease expenses and eliminate unneces-
sary costs by optimizing resource use.
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368The incidence of peripheral arterial occlusive disease
(PAOD) in Western societies is increasing due to an overall
increase of cardiovascular disease, diabetes mellitus, hyper-
tension, and obesity.1-5 This increased incidence of PAOD
directly results in increased overall health care-related costs
as well as specific treatment-related costs. The treatment-
related costs of PAOD vary, ranging from minimal costs for
conservative therapy to maximal costs for repetitive surgical
interventions. Especially postinterventional complications,
such as redo bypass surgery, result in prolonged hospital
admission and reoperation procedures, ultimately leading
to increased health care costs.6-8
In general, the treatment aim is to ensure that the
patient has a clinically optimal solution with long-term
benefits in an acceptable economic frame. In times of
restricted health care budgets, a detailed insight into the
costs related to treatment of specific diseases such as PAOD
is essential to constrain unlimited health care expenses and
to implement measurements to reduce health care costs.
Whatever reimbursement system is used, if one wants to
investigate cost-effectiveness of treatment modalities from
a hospital perspective, the actual cost is the preferred value
to analyze.9,10
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 2 Flu et al 369Many cost-identification analyses of treatment of
PAOD have focused on the intervention itself.9,10 Treat-
ment cost of PAOD can be divided by primary treatment
expenses and secondary costs due to postprocedural com-
plications. These complication-related costs are frequently
caused by wound care management, prolonged lengths of
stay in the intensive care unit (ICU) and the hospital, and
reoperations. To our knowledge, a specific detailed analysis
of complication-related cost of treatment of PAOD has not
been published.
The goal of this study was to perform a detailed cost-
evaluation of patients admitted and treated for PAOD. This
analysis assessed the actual costs of primary treatment,
including preoperative work-up and primary intervention;
furthermore, complication-related costs were identified.
Causes and consequences of complications were also regis-
tered and related expenses assessed.
METHODS
Patients. A 6-month survey was performed on 90
consecutive patients admitted and treated for PAOD from
January 2007 until July 2007. Criteria for inclusion in the
study population were intermittent claudication (IC) or
critical lower limb ischemia (CLI). IC was defined as ex-
tremity pain, discomfort, or weakness that is consistently
produced by the same amount of walking or equivalent
muscular activity in a given patient and that is promptly
relieved by cessation of that activity, with a pain-free walk-
Table I. Baseline characteristics, classified according to th
absence (group A) or presence (group B) of complications
Characteristicb Total
Patients, No. 90
Gender
Male 53 (59)
Female 37 (41)
Age, years
Mean (SD) 71.4 (13.3)
Range 46-93
Fontaine classification
2b 12 (13)
3 25 (28)
4 53 (59)
ASA classification14
2 41 (46)
3 43 (48)
4 6 (7)
Comorbidity (SVS-ISCVS)
Cardiac disease 53 (59)
Pulmonary disease 21 (23)
Renal disease 11 (12)
Carotid disease 14 (16)
Diabetes mellitus 31 (34)
Hyperlipidemia 21 (23)
Hypertension 48 (53)
Tobacco use 29 (32)
ASA, American Society of Anesthesiologists; SD, standard deviation; SVS-IS
of Cardiovascular Surgery.
aData are presented as number (%), unless otherwise specified.ing distance 100 m and an ankle pressure (AP) afterexercise of 50 mm HG (Fontaine stage 2b). This corre-
sponds with category 3 of the Society of Vascular Surgery/
North American Chapter of the International Society for
Cardiovascular Surgery (SVS/ISCVS) standards.11,12 CLI
was defined as ischemic rest pain (Fontaine 3) with a resting
AP of40 mm HG, and gangrene or nonhealing ischemic
ulceration (Fontaine 4) with a resting AP of60 mm HG.
This corresponds with categories 4, 5, and 6 of the SVS/
ISCVS. At admission, patients without complications were
placed in group A and those with complications in group B.
This adjustment of the two groups allowed a meaningful
comparison of costs related to complications.
Risk factors and comorbidities. Risk factors and co-
morbidities were registered prospectively for all patients
during their admission intake. Smoking, hypertension, car-
diac disease, hyperlipidemia, diabetes mellitus, renal dis-
ease, pulmonary disease, carotid disease, and age were
classified according to the SVS/ISCVS standards.11,12 The
risk factor and comorbidity management was conducted by
a vascular specialist or cardiologist preoperatively in the
outpatient clinic or during admission, before operation,
when urgent intervention was indicated. The American
Society of Anesthesiologists (ASA) classification13 of pa-
tients was prospectively determined according to their gen-
eral preoperative condition. Data for the risk factors and
comorbidities are listed in Table I.
Treatment of PAOD. Treatment was divided in non-
surgical, endovascular, and surgical (vascular and nonvas-
S/ISCVS standards,11,12 of the 90 patients stratified by
Group A Group B P
40 50
.848
24 (60) 29 (58)
16 (40) 21 (42)
.269
67.4 (13.1) 74.6 (12.7)
36-88 39-93
.001
12 (30) 7 (0)
15 (38) 10 (20)
13 (33) 40 (80)
.001
27 (68) 14 (28)
13 (33) 30 (60)
0 (0) 6 (12)
15 (38) 38 (76) .001
10 (25) 11 (22) .738
1 (3) 10 (20) .012
2 (5) 12 (24) .013
13 (33) 18 (36) .728
10 (25) 11 (22) .738
19 (48) 29 (58) .321
15 (38) 14 (28) .338
ociety of Vascular Surgery/North American Chapter, International Societye SV
CVS, Scular) treatment. The nonsurgical treatment in our study
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room, including local pain or wound management, antibi-
otic therapy, and superficial necrosectomy performed on
the ward and not in the operating room.
Endovascular treatment reflected urokinase treat-
ment14-17 and percutaneous transluminal angioplasty
(PTA). The technique of thrombolysis used and the doses
of urokinase administered were at the discretion of the
interventional radiologist. PTA was done with conven-
tional balloon dilatation of the lesion, with or without stent
placement. The vascular surgical treatment consisted of
thrombectomy, endarterectomy, or a bypass graft proce-
dure. Bypass grafting was performed according to standard
vascular techniques, using preferably reversed vein for in-
frainguinal femoropopliteal, crural, or pedal bypass proce-
dures, and Dacron or polytetrafluoroethylene (PTFE) for
aortofemoral and femorofemoral bypass grafting. All these
vascular operations were performed by or under the super-
vision of a vascular surgeon.
The nonvascular surgical treatment consisted of drain-
age/débridement, a minor amputation, defined as toe or
transmetatarsal amputation, or a major amputation, de-
fined as an amputation above or below the level of the knee.
Complications: causes and consequences. The fol-
lowing general definition of a complication developed by
the Association of Surgeons of the Netherlands (ASN)18-20
was used: a complication is a condition or event, unfavor-
able to the patient’s health or treatment, causing uninten-
tional damage or requiring a change in therapeutic policy or
additional treatment, which arose during admission or30
days after discharge. A patient admitted with gangrenous
toes, who then required amputation after a successful limb-
saving vascular reconstruction, was not considered as a
complication. However, gangrenous toes were considered
a complication if they developed during the hospital stay
after vascular reconstruction and ultimately required ampu-
Table II. Costs after treatment for peripheral arterial occl
Appraisal of costsa Total (€) Gro
Primary treatment 568,570 25
Pre-op workup 128,739 5
Non-surgical 2381
Endovascular 217,643 9
Surgical 219,807 9
After primary treatment 1,148,282 26
Pharmacy 12,530
Admission 1,034,511 25
Laboratory services 24,238
Imaging 8961
Consulting specialists 14,609
Proceduresb 53,432
Total
Costs 1,716,852 51
Percentage, % NA
Per patient 19,076 1
Group A, Patients without complications; Group B, patients with complicat
aData are presented as euros (€), unless otherwise specified.
bSurgical and endovascular.tation.All interventions performed during the hospital stay
that were unforeseen at the time of admission were consid-
ered complications and calculated as such. In this compli-
cation registration system, the most severe complication
was coded. For instance, if a patient had a myocardial
infarction and recovered, then of course, this was coded as
a myocardial infarction, but if a patient died from a myo-
cardial infarction, this was coded as death. Thus, the most
invasive or most severe consequence of each complication
was coded. This way of classification enabled us to evaluate
the most severe adverse events in our practice.
In brief, a complication is identified by one of the
physicians in our surgical team who documents the com-
plication in an electronic medical file real-time. This file is
operational throughout the hospital and the outpatient
clinic, which makes recording easy. In-hospital docu-
mented complications are automatically presented at the
daily surgical conference in the morning and the afternoon.
All causes of the complications and their consequences
were coded weekly according to our complication registra-
tion system21,22 as listed in the protocol outlined in Appen-
dix I (online only). All senior surgeons, residents, and
interns joined this weekly meeting.
Appraisal of costs. To determine the economic effect
of health care services on the budget, estimates of actual
economic costs are required to represent the value of the
resources used. As listed in Appendix II (online only),23-25
cost data were obtained from several hospital accounting
databases. As listed in Table II and Appendix II, total
hospital costs were divided by “primary treatment” and
costs “after primary treatment.”
As listed in Appendix II, costs of the primary treatment
included the costs of the preoperative workup and standard
initial care (nonsurgical, endovascular, or surgical). For
example, patients with gangrenous toes at the time of
admission who underwent successful limb-saving vascular
disease by group and subanalysis of patients who died
(€) Group B (€) Patients who died (€)
317,278 123,180
72,300 29,022
1191 1191
123,460 62,403
120,328 30,564
886,763 274,626
12,530 1815
780,111 243,200
20,695 6001
7937 4868
12,059 3897
53,432 14,843
1,204,042 397,807
.9 70.1 23
24,081 24,862
A, not applicable.usive
up A
1,292
6,439
1191
4,183
9,480
1,518
. . .
4,400
3543
1025
2550
. . .
2,811
29
2,820
ions; Nreconstruction, followed by toe amputation, were not con-
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grenous at admission and all costs were primary treatment-
related costs.
The costs after primary treatment included the costs of
additional medication or transfusion (antibiotics, neurol-
ogy, cardiac, and blood bank), the total length of stay
(defined as the number of days from date of admission to
date of discharge), clinical laboratory services (hematology,
microbiology, and chemistry), imaging (x-ray, ultrasound,
computed tomography scan, duplex ultrasound imaging,
and electrocardiography), consulting specialist, and sec-
ondary surgery. For example, if a patient developed gangre-
nous toes during admission after vascular reconstruction,
ultimately leading to amputation, this was considered a
complication (as defined by our complication registration
system), and all costs related to this amputation were costs
after primary treatment. Important to mention is that in-
cluded in the costs of the primary treatment and after
primary treatment were the fees of the various staffs, includ-
ing duplex ultrasound technicians, laboratory, hematology/
microbiology laboratory, and angiography; consultants (in-
ternal medicine, cardiology, and neurologist), radiologists,
anesthesiologists, operating room staff, and the vascular
surgeon. All costs in this article were calculated in 2007
euros (€) and were defined as average estimated total costs.
Registration and statistical analysis. An Access data-
base (Microsoft Corp, Bellingham, Wash) was used to enter
patient information for a specifically designed computer-
ized analysis program for vascular patients. Statistical anal-
yses were performed through a computerized software
package, using Excel (Microsoft) and SPSS 12.01 software
(SPSS Inc, Chicago, Ill). The Fisher exact test, Student t
test, or 2 test were used to assess differences between both
groups for a given parameter. The secondary procedures
were analyzed with the Mann-Whitney U test. For all
statistical analyses, a value of P  .05 was considered to be
statistically significant.
RESULTS
Patients. Fifty-three men (59%) and 37 women (41%)
underwent treatment. Mean age was 71.4 years (range,
36-93 years). Indication for treatment of PAOD was Fon-
taine 2b in 12 patients (13%), Fontaine 3 in 25 (28%) and
Fontaine 4 in 53 (59%). Mean duration of admission was 14
days (range, 1-80 days). The 30-day postoperative mortal-
ity rate was 13%. Patients’ characteristics in terms of sex,
age, Fontaine and ASA classification, and comorbidity are
listed in Table I.
Risk factors and comorbidity. No sex or age differ-
ences were found between the groups as listed in Table I.
Patients in group B had a significantly higher Fontaine classi-
fication and also had a significantly higher ASA classification
for cardiac disease (P  .001), renal disease (P  .012), and
carotid disease (P  .013). No differences were found be-
tween the groups for pulmonary disease (P .738), diabetes
mellitus (P .728), hyperlipidemia (P .738), hypertension
(P .321), and tobacco use (P .338).Treatment. As listed in Table III, no differences were
found between the groups for primary treatment: six non-
surgical (7%, n  6), endovascular (35%, n  32) and
surgical (58%, n  52). As listed in Tables IV and V, 115
complications were registered from the time of admission
among the entire group of 90 patients during the 30-day
postoperative period. Compared with the patients in group
A, those in group B underwent significantly more second-
ary treatment (P  .001) because of postoperative compli-
cations.
Patients without complications. As listed in Table I,
group A comprised 40 patients, 24 men (60%) and 16
women (40%), with a mean age of 67.4 years (range, 36-88
years) years. Indication for treatment of PAOD was Fon-
taine 2b in 12 patients (30%), Fontaine 3 in 15 (38%), and
Fontaine 4 in 13 (33%); and 68% were classified as ASA 2.
Mean duration of admission was 7.4 days (range, 1-17
days). Primary treatment consisted of nonsurgical treat-
ment in three patients (8%), endovascular treatment in 15
(38%), and surgical treatment in 22 (56%).
Patients with complications. As listed in Table I,
Table III. Therapy at admission of the 90 study patients
and stratified by absence (group A) or presence (group B)
of complications
Treatmenta Total Group A Group B P
Primary treatment 90 (100) 40 (44) 50 (56) .817
Nonsurgical
Wound, pain
treatment 6 (7) 3 (8) 3 (6)
Endovascular
Urokinase 13 (14) 5 (13) 8 (16)
PTA  stent 19 (21) 10 (25) 9 (18)
Surgical
Vascular
Thrombectomy 3 (3) 1 (3) 2 (4)
Endarterectomy 
patch 8 (9) 4 (10) 4 (8)
Bypass graft 26 (29) 14 (35) 12 (24)
Nonvascular
Drainage/
débridement 1 (1) 0 (0) 1 (2)
Minor amputation 5 (6) 3 (8) 2 (4)
Major amputation 9 (10) 0 (0) 9 (18)
Secondary treatment 13 (100) 0 (0) 13 (100) .001
Endovascular
PTA  stent 2 (15) 0 (0) 2 (15)
Surgical
Vascular
Thrombectomy 1 (8) 0 (0) 1 (8)
Endarterectomy 
patch 3 (23) 0 (0) 3 (23)
Bypass graft 1 (8) 0 (0) 1 (8)
Nonvascular
Drainage/
débridement 4 (31) 0 (0) 4 (31)
Major amputation 2 (15) 0 (0) 2 (15)
PTA, Percutaneous transluminal angioplasty.
aData are presented as number (%).group B comprised 50 patients, 29 men (58%) and 21
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years). Indication for treatment of PAOD was Fontaine 3 in
10 patients (20%) and Fontaine 4 in 40 (80%), and 60%
were classified ASA 3. Primary treatment consisted of con-
servative treatment in three patients (6%), endovascular
treatment in 17 (34%), and surgical treatment in 30 (60%).
A total of 13 secondary procedures (2 endovascular, 5
vascular, 6 nonvascular treatments) were the consequences
of 115 postoperative complications during the 30-day post-
operative period (Tables III and IV). The mean duration of
admission was 19.5 days (range, 5-80 days).
As listed in Table VI, 16 patients (17.7%) died during
admission, and 12 (13%) died 30 days postoperatively.
Mean age was 82 years (range, 61-93 years). Indication for
treatment of PAOD was Fontaine 3 in three patients (19%)
and Fontaine 4 in 13 (81%), and 81% were classified as ASA
3 and 13% as ASA 4. The primary treatment was nonsurgi-
cal in six patients (38%), endovascular in two (12%), and
surgical in 8 (50%). Mean duration of admission was 19
days (range, 5-53 days).
Complications: causes and consequences. As listed
in Tables IV and V, 115 complications were registered.
Shortcomings in patient management (group I) reflected
28% of all complications, of which, 47% resulted in addi-
tional medication or transfusion, 25% were minor with no
long-term consequence, and 22% resulted in a prolonged
hospital stay. Shortcomings in surgical technique (group
Table IV. Complications in the 90 patients after
treatment for peripheral arterial occlusive disease
Complication (cause) No. (%)
Total complications 115
Shortcomings in patient management 32 (28)
Shortcomings in medication 4 (3)
Blister 4 (3)
Cardiac failure 3 (3)
Renal failure 7 (6)
Other 14 (12)
Shortcomings in surgical technique 20 (17)
Hemorrhage 3 (3)
Abscess 1 (1)
Wound infection 6 (5)
Wound dehiscence 2 (2)
Wound hematoma 2 (2)
Bypass graft procedure
Infection 1 (1)
Occlusion 4 (3)
Thrombosis 1 (1)
Patient’s disease 56 (49)
Cardiac failure 16 (14)
Pulmonary failure 5 (4)
Renal failure 3 (3)
Death 16 (14)
Other 16 (14)
Outside surgical department 7 (6)
Hemorrhage 4 (3)
Wound infection 1 (1)
Bypass graft occlusion 1 (1)
Cardiac failure 1 (1)II) reflected 17% of all complications, of which 45% re-sulted in a surgical reoperation, 30% resulted in additional
medication or transfusion, and 20% were minor complica-
tions with no long-term consequence. Complications re-
lated to the patient’s disease (group III) reflected 49% of all
complications, of which 54% resulted in additional medica-
tion or transfusion and 29% resulted in the most severe
consequence, early death. Complications that occurred
outside the surgical department (group IV) reflected 6% of
all complications, of which 43% resulted in a prolonged
hospital stay and 29% resulted in additional medication or
transfusion.
In total, additional medication or transfusion was the
consequence of 46% of all consequences, mainly caused by
complications related to the patient’s disease (group III)
and shortcomings in patient management. Prolonged hos-
pital stay (14%) was mainly caused by shortcomings in
patient management. A surgical reoperation occurred in
12% of all consequences and was mainly caused by a short-
coming in surgical technique (group II).
The 16 patients who died sustained 49 complications
(43%), including the complication of death itself (Table
VI). Shortcomings in patient management (group I) re-
flected 18% of these complications, shortcomings in surgi-
cal technique (group II) reflected 14%, and complications
related to the patient’s disease (group III) reflected 67%.
Appraisal of costs. As listed in Table VII, the Fon-
taine 4 patients were responsible for 70.2% (€1,203,459) of
the total costs; they were two times more expensive com-
pared with the Fontaine 2b patients. According to the ASA
classification, ASA 3 patients were responsible for 48.4%
(€830,555) of the total costs; however, the ASA 4 patients
were two times more expensive compared with the ASA 2
patients.
The costs of the treatment for PAOD of the 90 patients
were €1,716,852 during the study period (Table II). The
complication group consumed 70.1% of this amount, re-
sulting in a difference of €691,231 in total costs and in costs
per patient of €11,261 between both groups. The primary
treatment (€317,278), admission days (€780,111), and
secondary procedures (€53,432) were main drivers of the
costs in the complication group.
For the patients without complications, the two main
costs were primary treatment (€251,292) and admission
days (€254,400). There was no difference in the costs per
patient for primary treatment comparing group A (€6282)
with group B (€6346). However, a difference of €11,197
was seen in case of the costs per patient after primary
surgery between group A (€6538) and group B (€17,735).
The mean length of admission in group B of 19.5 days (P
.068) caused a difference of €9242 in costs of the length of
stay in the hospital.
As listed in Table VII, the 115 complications caused
costs after treatment for PAOD of €568,500; they con-
sumed 33.1% of the total costs, with costs per complication
of €4943.
A shortcoming in surgical technique (group II) was the
most expensive complication, consuming 28.7% of the total
complication costs with complication costs of €8157. This
taine
Comp
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(€5961) and secondary surgery (€1882). The complica-
tions cost of patient’s disease (group III) was €5171,
amounting to 50.9% of the total complication cost, of
which €4572 was mainly a result caused by mean costs of
admission days. Shortcomings in patient management
(group I) and complications outside the surgical depart-
ment (group IV) represented the less expensive groups of
complications, respectively €2998 and €2837 of complica-
tion costs.
The total costs of the consequences of the 115 compli-
cations were also evaluated, as listed in Tables II and VII.
Surgical reoperation (group 2A) was the most expensive
consequence; it consumed 20.8% of the total consequence
costs, with a mean consequence cost of €9081. This
amount was primary caused by costs of admission days
(€4924) and secondary surgery (€3847). Additional medi-
Table V. Complications (causes and consequences) after t
sample (n  115)
Complication causes Total 1A
Shortcomings
In patient management 32 (28) 8 (25)
Surgical technique 20 (17) 4 (20)
Patient’s disease 56 (49) 1 (2)
Outside surgical dept 7 (6) 1 (14)
Total 115 (100) 14 (12)
a1A, Minor complication, no long-term consequence; 1B, additional med
irreversible physical damage; 4, death.
Table VI. Baseline characteristics of the 16 patients who d
Patient Sex; age (y) Classa LOS, days Primary treatme
1 M; 90 A3; F4 11 Wound and pain trea
2 M; 61 A3; F4 6 Urokinase
3 F; 85 A3; F4 15 Urokinase
4 F; 80 A3; F4 7 Urokinase
5 F; 89 A3; F4 50 Urokinase
6 M; 72 A3; F3 5 Urokinase
7 F; 93 A3; F3 7 Urokinase
8 F; 89 A3; F3 19 PTA  stent
9 M, 80 A3; F3 7 Endarterectomy  pa
10 M; 76 A2; F4 53 Endarterectomy  pa
11 F; 89 A3; F4 12 Bypass graft
12 M; 80 A3; F4 53 Bypass graft
13 M; 77 A3; F4 30 Bypass graft
14 F; 86 A3; F4 6 Major amputation
15 M; 87 A4; F4 7 Major amputation
16 M; 83 A4; F4 16 Major amputation
AF, Atrium flutter; BGP, bypass graft procedure; CHF, congestive heart
multiorgan failure; PTA, percutaneous transluminal angioplasty; UTI, urina
aAccording to the American Society of Anesthesiologists (A)13 and the Fon
bImportant to stress is that the complication “death” is not included in thecation or transfusion (group 1B) consumed 61.3% of thetotal consequence costs, with consequence costs of €6572,
of which €6159 occurred from mean costs of admission
days. Prolonged hospital stay (group 2B) only contributed
10.6% to the total consequence costs, with a mean conse-
quence cost of €3778. The minor complication with no
long-term consequence (group 1A), the irreversible physi-
cal damage (group 3), and death (group 4) represented the
least expensive groups of consequences, with respectively
costs of €2210, €2505, and €203.
The period before the actual occurrence of a patient’s
death reflects increased admission days (n  304) because
of the occurrence of 43% of all registered complications in
these patients. As listed in Table II, the costs after primary
treatment (€274,626) of these patients reflect 31% of the
costs after primary treatment of all patients with complica-
tions (€886,763). The total costs of these 16 patients
(€397,807) reflect 23% of the total costs (€1,716,852) of
ent for peripheral arterial occlusive disease of the total
Consequence, No. (%)a
B 2A 2B 3 4
(47) 1 (3) 7 (22) 1 (3) 0 (0)
(30) 9 (45) 1 (5) 0 (0) 0 (0)
(54) 2 (4) 5 (9) 2 (4) 16 (29)
(29) 1 (14) 3 (43) 0 (0) 0 (0)
(46) 13 (12) 16 (14) 3 (3) 16 (14)
or transfusion; 2A, surgical reoperation; 2B, prolonged hospital stay; 3,
during the study period
Complicationsb Cause of death
t None Septicemia
None Cardiac failure
None Unknown
Cardiogenic shock Cardiac failure
CHF, MI, feces culture, other neurology Respiratory failure
Wound hematoma Septicemia
Wound hematoma, other neurology Cardiac failure
UTI, renal failure, electrolytes failure,
decrease Hb, fracture
MOF
Thrombosis BGP, pneumonia, CHF Respiratory failure
Abscess, feces culture Unknown
Occlusion BGP feces culture Unknown
Patient management, wound dehiscence
pneumonia, AF, asystolic, other
neurology
Cardiac failure
Hypotension, AF, other neurology Respiratory failure
None MOF
CHF, renal failure Cardiac failure
Wound dehiscence, feces culture Unknown
; Hb, hemoglobin; LOS, length of stay; MI, myocardial infarction; MOF,
ct infection.
classification (F).
lications.reatm
1
15
6
30
2
53
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The primary goal of this study was to provide insight in
actual cost of treatment of PAOD in general and of addi-
tional cost of postprocedural complications. The secondary
goal was to analyze costs related to specific causes and
consequences of complications. Cost-efficiency of treat-
ment of PAOD is important in today’s world of financial
constraints on health expenditure. Valid cost-estimates may
help identify the optimal treatment strategy for patients
with PAOD. Cost-accounting methods introduced in hos-
pitals nationwide should improve cost-estimates substan-
tially. The in-hospital financial burden of treating PAOD
can be divided into the cost of primary treatment and the
cost after primary treatment (Table II) and is considerable
during admission. Of most concern in this respect is the
excessive financial burden that each failed intervention pro-
cedure (either endovascular or surgical) can place on our
vascular unit. The study population included all patients
admitted and treated for PAOD during a defined period
from a defined population and therefore provides a good
insight in the economic consequences of PAOD treatment.
We make several observations that advance this field of
Table VII. Costs divided by Fontaine classification,
American Society of Anesthesiologists classification, and
complications
Category No. Total € %
Per
patient, €
Diagnosis & comorbidity
Fontaine classification
2b 12 133,400 7.8 11,117
3 25 378,005 22 15,120
4 53 1,203,459 70.2 22,707
ASA classification13
2 41 678,775 39.6 16,555
3 43 830,555 48.4 19,315
4 6 205,534 12 34,256
Complications
Causes
Group I 32 95,924 16.9 2998
Group II 20 163,137 28.7 8157
Group III 56 289,578 50.9 5171
Group IV 7 19,861 3.5 2837
Total 115 568,500 NA 4943
Consequences
Group 1A 14 30,939 5.4 2210
Group 1B 53 348,293 61.3 6572
Group 2A 13 118,054 20.8 9081
Group 2B 16 60,451 10.6 3778
Group 3 3 7516 1.3 2505
Group 4 16 3248 0.6 203
Total 90 1,716,852 NA 19,076
ASA, American Society of Anesthesiologists; NA, not applicable; Group I,
shortcomings in patient management; Group II, shortcomings in surgical
technique; Group III, patient’s disease; Group IV, outside surgical depart-
ment; Group 1A, minor complication, no long-term consequence; Group
1B, additional medication or transfusion; Group 2A, reintervention by
surgeon; Group 2B, prolonged hospital stay; Group 3, irreversible physical
damage; Group 4, death.inquiry.First, we found statistically significant differences of
pretreatment symptoms (Fontaine classification) and co-
morbidity (ASA classification) between group A and B.
Concerning the costs represented by the Fontaine and the
ASA classifications, an elevating trend was observed in
accordance with the classification. This could be explained
by the fact that the patients (group B) classified Fontaine 4
or ASA 3 or 4, or both, have the highest form of PAOD and
represent a high-comorbidity group of patients. Both result
in the most expensive form of preoperative workup and a
high incidence of postoperative complication-related costs.
Fontaine 4 and ASA 4 patients were twice as expensive as
Fontaine 2b and ASA 2 patients, respectively.
Second, no differences were found concerning the kind
of primary treatment between group A and B resulting in
approximately the same costs per patient in both groups
(€6300). The overall costs of the primary treatment re-
flected 33% of the total costs.
Third, the results of our analyses indicate that consid-
erable extra costs are incurred because of complications
after treatment of PAOD, which increased the total costs
per admission substantially. The overall costs of the com-
plications reflected 33% of the total costs. The shortcoming
in surgical technique (group II) was the most expensive
cause of a complication, and the patient’s disease (group
III) consumed half of the total complication costs. A likely
explanation for these high additional costs is that patients
with complications need longer hospitalization (secondary
procedures) and may require more additional care than
other patients. Shortcomings in patient management
(group I) and surgical complications (group II) are causes
of complications that could be prevented by structured
changes in perioperative management and surgical proto-
col; they are susceptible for improvement and thereby cost
reduction. Prevention of the occurrence of these causes of
complications would result in a significant reduction in
costs, because they are responsible for 45.6% of the addi-
tional costs.
Fourth, patients in group B tended to undergo second-
ary treatment more frequently. If a secondary treatment
was involved, a new workup, extra admission time, and the
procedure itself added to the total costs. Costs associated
with secondary treatment constituted 20.8% of the total
costs of the consequences and reflected the most expensive
consequence per complication (€9081). Additional me-
dication or transfusions were responsible for 61.3% of the
costs of all consequences.
Fifth, the consequence of death itself was not very
expensive; however, the patients who died reflect a group
that is responsible for 23% of the total costs of all patients.
The period before the patient actually dies is a very expen-
sive period because of the occurrence of 43% of all regis-
tered complications, automatically resulting in an increased
admission period and therefore increasing total costs.
Sixth, as we realize, complications will always occur in
every surgical department, and it is an illusion to strive for a
practice without any complications. However, our goal is
to strive for the highest possible quality of care with as few
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 2 Flu et al 375as possible adverse events. We do realize that owing to
extensive preoperative comorbid conditions, especially in
our specific patient population, complications are inevita-
ble. In this and in previous studies from our clinic,21,22
however, we observed that shortcomings in patient man-
agement or in surgical technique caused a significant por-
tion of all complications. Especially these two categories are
human errors and, therefore, these complications are pre-
ventable. For instance, one of the most frequent registered
complications caused by shortcomings in patient manage-
ment was postoperative fluid overload ultimately leading to
congestive heart failure and even myocardial infarction.
After analyzing the cardiac adverse events that were caused
by shortcomings in patient management, we altered the
postoperative fluid protocol to prevent these adverse
events.
The Dutch financial health care system is still develop-
ing its methods of cost calculations. In January 2006, a
fairly rigid budget system, diagnosis treatment code
(DTC),23 was introduced to constrain hospital charges. In
this system, a diagnosis is related to a standardized budget
per year. For instance, health care insurance companies
reimburse the combination of the diagnosis with its treat-
ment. These DTC prices are negotiated between individual
health care providers and health care insurance companies.
In this DTC, the specific treatment ranging from conserva-
tive treatment to extensive surgical interventions is not
predefined.
This study indicates that complication-related costs of
the treatment of PAOD are strongly correlated with the
ASA and Fontaine classifications. The recently imple-
mented Dutch DTC system does not take into account the
classifications for these preoperative patient-specific comor-
bidities and specific severity of disease. In a system in which
health care providers receive standardized, up-front nego-
tiated reimbursements independent of the patient case mix
that is treated, health care physicians possibly tend to treat
patients with minor comorbidities to reduce the incidence
of postoperative complications and thereby costs.
This study is limited by its size of 90 patients, of which
40 patients were without complications and 50 patients had
complications. A limitation of this study may be the restric-
tion of data collection from only one hospital, which might
not be completely representative for all hospitals. Also the
sample was composed exclusively of patients with PAOD;
therefore, these financial results may not generalize to other
vascular patient samples.
We acknowledge that all complication registration sys-
tems will have some sort of underestimation. However, we
believe our registration system contains several crucial as-
pects, such as a prospective registration twice a day on the
day of the occurrence of the complication (instead of
registration at the time of discharge), and a plenary evalu-
ation of all complications once a week in an open, construc-
tive, nonaccusing atmosphere. These aspects will limit un-
der registration of complications and complication related
costs.CONCLUSIONS
These results suggest that complications cause a signif-
icant increase in the costs of treatment for peripheral arterial
occlusive disease. Shortcomings in surgical technique and
the patient’s disease were the most expensive causes of
complications. Surgical reoperation or alteration of addi-
tional medication, or both, or transfusion were the two
most expensive consequences of complications. We firmly
believe vascular surgeons should take a leading role in
helping to decrease health care expenses. A principle
method to decrease hospital costs includes treatment strat-
egies aimed at prevention of shortcomings in patient man-
agement and shortcomings in surgical technique.
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Categorya Cause of the complicationb Consequence of the complication
Cardiac
Pulmonary
Renal
Neurology
(Sub)cutis
Hematology
Vascular management
I—Shortcomings in patient management
II—Shortcomings in surgical technique
IIII—Patient’s disease
IVI—Outside surgical department
1A—Minor complication, no long-term consequence
1B—Additional medication or transfusion
2A—Reintervention: by surgeon
2B— Prolonged hospital stay
3—Irreversible physical damage
4—Death
Patient’s disease: a potential life threatening complication caused by extensive pre-operative co-morbidity although all protective measurements were applied,
such as: postoperative congestive heart failure in a patient with extensive cardiac co-morbidity.
Outside surgical department: complications caused by specialists other than surgical physicians, such as: pneumothorax after central venous catheter placement
by the anesthesiologists.
aThese categories were further subdivided.
bExplanation and definition of the causes of complications. Shortcomings in patient management: complications occurred because of shortcomings in the
management of patient care by surgeons, residents, or interns; such as, myocardial infarction caused by shortcoming in patient management due to accidentally
not prescribing proper cardioprotective medication as indicated by preoperative cardiac assessment. Shortcomings in surgical technique: a complication due to
surgical or endovascular treatment, such as: primary bypass graft occlusion.
Appendix II (online only). Summary of the appraisal of costs, what was calculated and from were the average
estimated total costs were obtained
Appraisal of costs Calculated items Cost obtainment
Primary treatment
Preoperative workup
DUSE/ECG Laboratory, staff fee, consumable items DTC23 department
Diagnostic angiography Angiography suite, staff fee,
consumable items
Financial department, radiology
Hematology/microbiology Laboratory, staff fee, consumable items DTC23 department; Financial department,
laboratory service
Pharmacy Medication Pharmacy Therapeutic Guide24
Consulting specialists Internal medicine, cardiology consult DTC23 department
Nonsurgical
Wound management Consumable items Financial department, vascular ward
Endovascular or surgical
procedures
Urokinase Medication Pharmacy Therapeutic Guide24; CHC25
Costs of the intervention Prosthetic materials, endovascular,
vascular, nonvascular, fees (vascular
surgeon, anesthesiologist,
radiologist, staff)
Financial, department anesthesiology;
CHC25
Operating room/recovery
room
Sterile and non-sterile consumable
items, medication, blood bank, IV
fluids
Financial department, laboratory service;
Pharmacy Therapeutic Guide24
Postoperative pain protocol Medication Pharmacy Therapeutic Guide24
After primary treatment
Pharmacy
Antibiotics Medication Pharmacy Therapeutic Guide24
Neurology/cardiac Medication Pharmacy Therapeutic Guide24
Hydration/dehydration Medication Pharmacy Therapeutic Guide24
Blood bank Laboratory, staff fee, consumable items Financial department, vascular ward
Admission
Bandage, urine catheter Consumable items Financial department, vascular ward
Length of stay ICU and vascular ward (days), staff fee,
service, housing
Financial department, vascular ward
Laboratory services
Hematology Laboratory, staff fee, consumable items Financial department, laboratory service
Microbiology (blood,
urine, feces)
Laboratory, staff fee, consumable items Financial department, laboratory service
Imaging
DUSE/ECG Laboratory, staff fee, consumable items DTC23 department
Diagnostic angiography,
x-ray/US/CT
Laboratory, fees (radiologist, staff),
consumable items
Financial department, radiologyConsulting specialists
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estimated total costs were obtained Continued.
Appraisal of costs Calculated items Cost obtainment
Internal medicine Fee, internal medicine consult DTC23 department
Cardiology Fee, cardiologist consult DTC23 department
Neurology Fee, neurologist consult DTC23 department
Endovascular or surgical
procedures
Costs of the intervention Prosthetic materials, endovascular,
vascular, nonvascular, fees (vascular
surgeon, anesthesiologist,
radiologist, staff)
CHC25; financial department,
anesthesiology;
Operating room/recovery
room
Sterile and nonsterile consumable
items, medication, blood bank, IV
fluids
Financial department, laboratory service;
Pharmacy Therapeutic Guide24
Postoperative pain protocol Medication Pharmacy Therapeutic Guide24
CT, computed tomography; DUSE, duplex ultrasound examination; ECG, electrocardiography; DTC, diagnosis treatment code; CHC, College of Healthcare
Costs; ICU, intensive care unit; IV, intravenous; US, ultrasound.
